Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 12 от 154

Набира участници Фаза 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast Neoplasms Neoplasm Metastasis

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

Начало: 22.12.2025 Край: 01.05.2033 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +15 Eli Lilly and Company NCT07174336

Набира участници Фаза 1/2

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

Hyperlipidemia; Mixed

Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.

Начало: 22.12.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

New Zealand Arrowhead Pharmaceuticals NCT07223658

Набира участници Фаза 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7806881 in Healthy Participants

Healthy Volunteers

The main purpose of this study is to evaluate the safety and tolerability of single and multiple ascending doses of RO7806881 in healthy participants.

Начало: 22.12.2025 Край: 01.03.2027 Възраст: 18–50 г. Лечение

New Zealand Hoffmann-La Roche NCT07271693

Набира участници Фаза 1/2

A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B

Chronic Hepaititis B

This is an open-label study with single- and multiple-ascending dose arms followed by a dose expansion arm. The primary objective of the study is to determine the safety and tolerability of CRMA-1001 in adult participants with Chronic Hepatitis B. In addition, the pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of CRMA-1001 will be evaluated. CRMA-1001 is an epigenetic gene therapy delivered via intravenous (IV) infusion. Up to four dose levels will be tested. Participants will receive a single or multiple doses of CRMA-1001 and will remain on antiviral therapy during the dosing process.

Начало: 22.12.2025 Край: 31.12.2032 Възраст: 18–64 г. Лечение

Hong Kong, New Zealand nChroma Bio NCT07200193

Набира участници Фаза 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

Начало: 19.12.2025 Край: 20.07.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +12 Janssen Research & Development, LLC NCT07225946

Набира участници

A Feasibility Study Implant of the WiSE® CRT System With an Intracardiac Pacemaker to Achieve Totally Leadless CRT

Heart Failure

Assess the safety and efficacy of the co-implantation of the WiSE CRT System with an intracardiac pacemaker to provide totally leadless CRT.

Начало: 18.12.2025 Край: 01.04.2027 Възраст: от 22 г. Лечение

Australia EBR Systems, Inc. NCT06561932

Набира участници

A Study on Hemolytic Disease of the Fetus and Newborn (HDFN) Through Global Registry

Hemolytic Disease of the Fetus and Newborn

The purpose of this non-interventional study is to prospectively evaluate the risk of anemia (decreased red blood cells) in fetuses (baby before birth) and neonates (baby just after birth) of pregnant participants who are at risk for hemolytic disease of the fetus and newborn (HDFN) and receiving standard of care (SoC). HDFN is a blood disease that occurs in babies before birth or just after birth when the blood types of the pregnant individual and babies are incompatible, thus resulting in fast breakdown of red blood cells (RBCs) of the fetus/baby.

Начало: 17.12.2025 Край: 30.09.2030 Възраст: от 18 г.

Australia, Germany, Italy +2 Janssen Research & Development, LLC NCT07194070

Набира участници Фаза 1/2

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

Melanoma (Skin) Non Small Cell Lung Cancer Breast Cancer

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2). The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalating doses of HMBD-501. The results of the dose escalation will determine the RP2D and dosing schedule of HMBD-501 to be administered in the Phase 2 part of the study. The primary objective of Phase 2 is to evaluate the preliminary clinical efficacy of HMBD-501 in dose expansion cohorts.

Начало: 17.12.2025 Край: 01.07.2027 Възраст: от 18 г. Лечение

Australia, United States Hummingbird Bioscience NCT06956690

Набира участници Фаза 1/2

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

Advanced Solid Tumors

The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processes OTP-01 by measuring drug levels in the blood. The main questions this study aims to answer are: * What is the recommended dose of OTP-01 for adults with solid tumors? * Is OTP-01 safe and tolerable? * Does OTP-01 reduce tumor growth? Participants will: * Receive OTP-01 through an infusion into a vein. Doses will be spaced out and never more than once a week. * Have blood tests to evaluate safety and drug levels of OTP-01. These will be done often at first and then less frequently as treatment continues. * Have radiographic scans of their tumor at baseline and during the study at regular intervals. * Have the choice to have an optional tumor biopsy before and after treatment to help researchers understand how OTP-01 affects cancer and the immune system. These biopsies are voluntary and will not affect participation in the study.

Начало: 17.12.2025 Край: 01.12.2028 Възраст: от 18 г. Друго

Australia, New Zealand, United States Ottimo Pharma Limited NCT07266428

Набира участници Фаза 3

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-Small-Cell Lung Cancer Metastatic Non-Small-Cell Lung Cancer Advanced Non-Small-Cell Lung Cancer EGFR P-Loop and Alpha C-Helix Compressing +2

Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC mutations, and who have not received any prior therapy for advanced disease. Participants will be randomized in a 1:1 ratio to treatment with firmonertinib or osimertinib or afatinib and will take the assigned dose daily.

Начало: 17.12.2025 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, Canada, Greece +10 ArriVent BioPharma, Inc. NCT07185997

Набира участници Фаза 1

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

Malignant Neoplasm

Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.

Начало: 16.12.2025 Край: 01.12.2030 Възраст: от 18 г. Лечение

Australia, Chile, Israel +3 Merck Sharp & Dohme LLC NCT07247110

Набира участници Фаза 1

Sapu003 in Advanced mTOR-sensitive Solid Tumors

Breast Cancer Metastatic Renal Cell Carcinoma (RCC) Neuroendocrine Tumors Tuberous Sclerosis Complex (TSC) +1

This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative breast cancer, renal cell carcinoma \[RCC\], neuroendocrine tumors \[NETs\], tuberous sclerosis complex \[TSC\]-associated tumors, and hepatocellular carcinoma \[HCC\]).

Начало: 15.12.2025 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia SAPU NANO (US) LLC NCT07369505

Набира участници Фаза 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Carcinoma, Transitional Cell Urinary Bladder Neoplasms Neoplasm Metastasis

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

Начало: 12.12.2025 Край: 01.05.2033 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +15 Eli Lilly and Company NCT07218380

Набира участници Фаза 2

A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Squamous Non-small Cell Lung Cancer

Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.

Начало: 12.12.2025 Край: 06.05.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Chile +6 Merck Sharp & Dohme LLC NCT07221474

Набира участници

A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Melanoma Metastatic Melanoma Advanced Solid Tumor Hepatocellular Carcinoma

This is a noninterventional, observational, long-term follow-up (LTFU) study. Patients in this study will be followed for 5 years from enrollment on this study to assess potential delayed risks of RPx products. Eligible participants for this LTFU study include patients who received at least 1 dose of an RPx product under the interventional parent study. Patients will be rolled over into this LTFU study after completion of the Replimune-sponsored parent study (ie, either completion of the LTFU in the parent study or withdrawal from the parent study). All patients in ongoing RPx studies will be asked to participate in this LTFU study so that the Sponsor can evaluate potential delayed risks.

Начало: 12.12.2025 Край: 01.12.2035 Възраст: от 18 г.

Australia, United States Replimune, Inc. NCT06887348

Набира участници Фаза 1

A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors

Advanced Solid Tumor

The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.

Начало: 11.12.2025 Край: 01.11.2028 Възраст: от 18 г. Лечение

Australia, China, Denmark +1 BeOne Medicines NCT07226349

Набира участници Фаза 3

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia Classic Congenital Adrenal Hyperplasia

The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.

Начало: 11.12.2025 Край: 01.05.2027 Възраст: 18–74 г. Лечение

Argentina, Australia, Brazil +4 Crinetics Pharmaceuticals Inc. NCT07144163

Набира участници Фаза 1

A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults

Healthy

The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07985631) for the possible treatment of a kidney disease called IgA nephropathy. This study is seeking participants who * are male or female between 18 and 45 years of age (55 for Japanese/Chinese/multiple dose participants) * are deemed to be healthy Participants in this study will receive PF-07985631 or placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. PF-07985631 or placebo will be given as a small needle injection (in the abdomen, thigh or back of the arm) at the study clinic. Most participants will receive PF-07985631 or placebo one time. Some participants may receive PF-07985631 or placebo twice. The study will compare the experiences of people receiving PF-07985631 to those of the people who do not. This will help decide if PF-07985631 is safe and effective. Participants who take PF-07985631 or placebo will take part in this study for about four- four and a half months. During this time, they will stay at the study clinic for 12 to 19 days and will have 7 more study visits at the study clinic. During study clinic stays and study visits, blood samples will be done and safety reviews completed.

Начало: 11.12.2025 Край: 24.08.2027 Възраст: 18–55 г. Фундаментална наука

Australia Pfizer NCT07235150

Набира участници Фаза 2

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

Clostridioides Difficile Infection

The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and above.

Начало: 10.12.2025 Край: 18.01.2028 Възраст: от 18 г. Превенция

Australia, Canada, Denmark +10 AstraZeneca NCT07285213

Набира участници Фаза 2/3

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan compared to standard of care (SOC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of NSCLC. This study will be divided into two stages, in the first stage (phase 2) participants will receive 1 of 2 doses of telisotuzumab adizutecan. In the second stage (phase 3) participants will receive the recommended phase 3 dose (RP3D) of telisotuzumab adizutecan, from the previous stage, or SOC. Approximately 430 adult participants with NSCLC will be enrolled in the study in 200 sites around the world. In phase 2, participants will receive 1 of 2 intravenous (IV) doses of telisotuzumab adizutecan. In phase 3, participants will receive the IV RP3D of telisotuzumab adizutecan, or SOC. The study will run for a duration of approximately 69 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Начало: 10.12.2025 Край: 01.09.2030 Възраст: от 18 г. Лечение

Australia, Belgium, China +9 AbbVie NCT07155187

1 … 10 11 12 13 14 … 154